The Credibility Crisis in Pharmaceuticals Marketing

Public trust in pharmaceutical companies is integral to the modern healthcare system. When people’s health is on the line, they expect extensive scientific rigor and ethics backing the treatments they are provided.

In the United States, where treatments quickly run into the hundreds of thousands of dollars, the premium on ethical advertisement is especially high. Patients rarely have the ability to independently judge the safety of drugs on their own, and so are often reliant on information provided to them by drug manufacturers.

Maintaining public trust requires more than scientific innovation; it requires clear and honest communication from pharmaceutical companies. When those standards are not met, the consequences affect corporate reputation and, more importantly, patient safety and public confidence in medicine itself.

Pfizer’s Vyndamax: five years of ATTR-CM market dominance

Pfizer’s marketing of Vyndamax, its commercialization of the tafamidis drug which is used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), is an instructive case study. ATTR-CM is a progressive heart disease caused by the accumulation of misfolded transthyretin proteins in the heart. This build-up causes the heart walls to become stiff, limiting the heart’s ability to fill with blood. ATTR-CM is a long-term and debilitating condition that requires ongoing treatment.

For five years, Pfizer’s Vyndamax was the only treatment on the market. It has been shown to reduce mortality and cardiovascular-related hospitalizations in patients with the condition. This drug alone accounts for 10% of Pfizer’s global revenue.

BridgeBio’s Attruby and Alnylam’s Amvuttra shake up the ATTR-CM market

But since 2024, the competitive landscape has changed.

BridgeBio's Attruby emerged as a significant rival in the ATTR-CM market, followed by Alnylam’s Amvuttra gaining FDA approval nearly half a year later. Like Vyndamax, Attruby works by stabilizing transthyretin proteins and preventing them from breaking apart and forming the amyloid deposits that drive disease progression.

While Amvuttra is too new to the market to know with certainty, Attruby is a very compelling option for people living with ATTR-CM. Despite this, Pfizer has chosen not to compete on price and efficacy, instead catching people’s attention through misleading marketing. This brings to light questions about marketing transparency and what it means to risk the faith of investors, patients, taxpayers, and the healthcare system at large.

Concerns raised over Pfizer’s marketing of Vyndamax

One key issue of contention is Pfizer’s claims that Vyndamax the “one standard of care” for ATTR cardiac amyloidosis. For instance, Pfizer's website still brands Vyndamax "the only" once-daily capsule for ATTR-CM. That word is backed by nothing more than a small footnote dated "as of July 2023." This lets the claim read as present-tense fact, and leaves phycisians and patients with an impression that is no longer accurate.

Further scrutiny followed a decision by a German court case surrounding Pfizer advertising that Vyndamax allows for “near complete stabilization’ of ATTR-CM.” The court determined that this was insufficiently supported by the drug’s data.

A history of concern over Pfizer’s marketing claims

The court case, and the fallout surrounding it, matters. It brings to light a historical pattern of misleading marketing by Pfizer. In one instance, the company breached regulations five times over its social media by making misleading claims, failing to maintain high standards, and promoting unlicensed medicines.

The United Kingdom’s pharmaceutical market watchdog, the Prescription Medicines Code of Practice Authority (PMCPA), specifically pointed out a post made by the medical director of Pfizer claiming the vaccine was 95% effective in preventing Covid-19. This was reposted by four of his colleagues, all of whom are accused of allowing “unlicensed medicine to be proactively disseminated on Twitter to health professionals and members of the public.”

Pfizer responded to this by vowing to “take all possible steps to avoid similar breaches of the code” in the future. Nevertheless, the PMCPA, found that these posts were still traceable in 2025, meaning that Pfizer failed to deliver on its commitment.

The future of the ATTR-CM market

Considering this precedent, it is understandable for patients and investors to have diminishing faith in the Pfizer brand, following a number of damaging cases that have accused the company of adopting misleading marketing practices.

On their heels are two insurgent biotech companies, BridgeBio and Alnylam, whose advancements in ATTR-CM treatment look set to erode Pfizer’s market share further.